Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2014-05-26Clinical Trial Update: A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 [Phase 1]
Phase 1 study to assess the effect of rifampin on the metabolism of ABT-199 (venetoclax) in Non-Hodgkin lymphoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-05-22Clinical Trial Update: Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy [Phase 1, Phase 2]
A Phase 1/2 clinical trial of noscapine in patients with low-grade non-Hodgkin lymphoma or chronic lymphocytic leukemia refractory to chemot…
-
CLINICAL_TRIALS trial_result · 2014-05-21Clinical Trial Update: Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating elsamitrucin (SPP 28090) in patients with relapsed or refractory Non-Hodgkin's Lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-05-20Clinical Trial Update: Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Velcade (bortezomib) in combination with rituximab for relapsed/refractory mantle cell lymphoma and follicular no…
-
CLINICAL_TRIALS trial_result · 2014-05-19Clinical Trial Update: Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer [Phase 3]
Phase 3 trial evaluating total-body irradiation with or without fludarabine phosphate followed by donor stem cell transplant in hematologic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating bendamustine (SDX-105) for safety and activity in patients with rituximab-refractory non-Hodgkin lymphoma; the stud…
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]
Phase 2 trial evaluating SDX-105 in combination with Rituxan for relapsed indolent or mantle cell Non-Hodgkin's Lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-05-08Clinical Trial Update: Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood [Phase 1, Phase 2]
Phase 1/2 trial evaluating Wilms' Tumor 1 protein vaccine for blood cancers has completed. Results were posted on 2014-05-08.
-
CLINICAL_TRIALS trial_result · 2014-05-07Clinical Trial Update: Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant [Phase 2]
Phase 2 study evaluating plerixafor to rescue poor mobilizers in autologous stem cell transplantation has completed; results were posted in …
-
CLINICAL_TRIALS trial_result · 2014-05-02Clinical Trial Update: Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas [Phase 2]
This is a Phase 2 clinical trial update for relapsed or refractory diffuse large B-cell non-Hodgkin lymphoma that has been terminated with r…
-
CLINICAL_TRIALS trial_result · 2014-05-01Clinical Trial Update: Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia [Phase 1]
Phase 1 trial evaluating obatoclax mesylate in combination with vincristine, doxorubicin, and dexrazoxane in pediatric patients with relapse…
-
CLINICAL_TRIALS trial_result · 2014-04-28Clinical Trial Update: Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study [Phase 3]
Phase 3 trial comparing bendamustine plus rituximab to R-CVP or R-CHOP in first-line advanced indolent non-Hodgkin's lymphoma or mantle cell…
-
CLINICAL_TRIALS trial_result · 2014-04-08Clinical Trial Update: Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody [Phase 2]
Phase 2 trial evaluating retreatment of non-Hodgkin lymphoma patients who previously responded to iodine-131 anti-B1 antibody; results were …
-
CLINICAL_TRIALS trial_result · 2014-04-07Clinical Trial Update: Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma [Phase 1, Phase 2]
This clinical trial update reports on the safety and tolerability results of PCI-24781 in patients with lymphoma, including Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2014-04-04Clinical Trial Update: Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) [Phase 3]
Phase 3 trial evaluating the effect of bendamustine in combination with rituximab on QT interval in patients with advanced indolent non-Hodg…
-
CLINICAL_TRIALS trial_result · 2014-03-31Clinical Trial Update: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 GAUSS study evaluating obinutuzumab in patients with indolent non-Hodgkin lymphoma has completed, with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-03-31Clinical Trial Update: T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies [Phase 2]
Phase 2 clinical trial evaluating T-cell depleted allogeneic stem cell transplantation for hematologic malignancies; study is completed with…
-
CLINICAL_TRIALS trial_result · 2014-03-28Clinical Trial Update: Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab in combination with the DexaBEAM salvage regimen for relapsed non-Hodgkin lymphoma has completed.
-
FDA approval · 2014-03-27FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS research · 2014-03-26Clinical Trial Update: Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination [Phase 1, Phase 2]
Open-label Phase 1/2 clinical trial evaluating the safety and tolerability of donor-derived allogeneic B-cell concentrates to support immune…
-
CLINICAL_TRIALS trial_result · 2014-03-20Clinical Trial Update: A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 study evaluating SGN-40 in combination with Rituximab in CD20-positive follicular and marginal zone B-cell non-Hodgkin's lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2014-03-17Clinical Trial Update: Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy [Phase 1]
A National Cancer Institute-sponsored Phase 1 trial evaluating sunitinib malate in HIV-positive cancer patients on antiretroviral therapy ha…
-
CLINICAL_TRIALS trial_result · 2014-03-11Clinical Trial Update: CART-19 Immunotherapy in Mantle Cell Lymphoma [Phase 1, Phase 2]
This clinical trial update reports a CART-19 immunotherapy being evaluated in Phase 1/2 for Mantle Cell Lymphoma, with the trial status curr…
-
CLINICAL_TRIALS trial_result · 2014-03-05Clinical Trial Update: Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat [Phase 1]
This is a Phase 1b trial update of AMG 655 in combination with bortezomib or vorinostat for lymphomas, including Hodgkin lymphoma and variou…
-
CLINICAL_TRIALS withdrawal · 2014-03-05Clinical Trial Update: Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
This Phase 1 trial evaluating donor T cells with low-dose aldesleukin and low-dose GM-CSF after donor stem cell transplant for relapsed or r…